非糜烂性胃食管反流病应用雷贝拉唑联合黛力新治疗的疗效分析

目的：探讨非糜烂性胃食管反流病应用雷贝拉唑联合黛力新治疗的效果。方法随机收集2014年1月—2016年6月入院的100例非糜烂性胃食管反流病患者随机分为两组，对照组患者给予雷贝拉唑治疗，实验组患者则给予雷贝拉唑联合黛力新治疗，比较两组患者总体治疗效果、GerdQ评分。结果实验组总有效率(94%)较对照组患者总有效率(78%)显著升高，差异有统计学意义(P<0.01)；治疗前GerdQ 评分(9.03±1.09)实验组与对照组患者(9.29±1.14)比较，差异无统计学意义(P>0.05)；治疗后，实验组患者 GerdQ 评分(5.12±1.12)较对照组患者 GerdQ 评分(9.03±1.09)显著降低，差异有统计学意义(P<0.01)；实验组较对照组患者不良反应情况比较，消化道不良反应、神经精神症状、药物过敏反应以及总不良反应率差异无统计学意义(P>0.05)。结论不论单用雷贝拉唑还是雷贝拉唑联合黛力新对非糜烂性胃食管反流病患者都有一定疗效，且不良反应发生的情况相近，均较少，但是是雷贝拉唑联合黛力新对非糜烂性胃食管反流病患者疗效更佳，降低GerdQ评分更显著，值得临床推广，具有借鉴性。

Analysis of Patients with Non -erosive Gastroesophageal Reflux Disease Rabeprazole Joint Deanxit Treatment

Objective To evaluate the efficacy of rabeprazole in combination with Deanxit in the treatment of non-erosive gastroesophageal reflux disease. Methods Random selection of 100 patients with non-erosive gastroesophageal reflux dis-ease admitted between January 2014 and June 2016 were randomized into two groups. In the control group, rabeprazole was given. In the experimental group, rabeprazole Combined with Deanxit treatment, compared the overall treatment effect of two groups of patients, GerdQ score. Results The total effective rate (94%) of the experimental group was significantly higher than that of the control group (78%), the difference was statistically significant(P<0.01);GerdQ score before treatment (9.03 ± 1.09) The GerdQ score in the experimental group was significantly lower than that in the control group (9.29 ± 1.14) (P<0.05). The GerdQ score (5.12 ± 1.12) in the experimental group was significantly higher than that in the control group (9.03 ± 1.09) (P<0.01). Compared with the control group, there were no significant difference in adverse reactions, gastrointesti-nal adverse reactions, neuropsychiatric symptoms, drug allergy reaction and total adverse reaction rate between the experi-mental group and the control group(P> 0.05), but the difference was not significant Statistical significance(P> 0.05). Con-clusion Both rabeprazole and rabeprazole combined with deanxitin have certain curative effect on non-erosive gastroe-sophageal reflux disease, and the adverse reactions are similar, but lesser, Zoloft combined with Deanxit for non-erosive gastroesophageal reflux disease in patients with better efficacy and lower GerdQ score more significant, worthy of clinical promotion, has reference.